Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 30, 2015 5:35 AM ET

Biotechnology

Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in Prader-Willi Syndrome patients; that has completed Phase II clinical trials for the treatment of hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which is in Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical studi...

One Broadway

8th Floor

Cambridge, MA 02142

United States

Founded in 2005

22 Employees

Phone:

617-401-3051

Key Executives for Zafgen, Inc.

Chief Executive Officer and Director
Age: 54
Total Annual Compensation: $425.0K
President
Age: 51
Total Annual Compensation: $195.4K
Chief Financial Officer
Age: 51
Total Annual Compensation: $297.9K
Chief Medical Officer
Age: 43
Total Annual Compensation: $407.0K
Chief Commercial Officer
Age: 51
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

Zafgen, Inc. Key Developments

Zafgen, Inc. expected to report Fiscal Year 2014 results on March 29, 2015. This event was calculated by Capital IQ (Created on March 23, 2015).

Zafgen, Inc. expected to report Fiscal Year 2014 results on March 29, 2015. This event was calculated by Capital IQ (Created on March 23, 2015).

Zafgen, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Zafgen, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported a net loss attributable to common stockholders of $10,931,000, or $0.48 per basic and diluted share compared to a $3,899,000 or $5.35 per basic and diluted share, for the three months ended December 31, 2013. Loss from operations was $10,664,000 compared with $3,761,000 for the same period a year ago. For the year, the company reported loss from operations of $35,532,000 against $13,780,000 a year ago. Net loss attributable to common stockholders was $36,570,000 or $3.00 per basic and diluted share against $14,240,000 or $19.53 per basic and diluted share a year ago.

Zafgen, Inc., Q4 2014 Earnings Call, Mar 19, 2015

Zafgen, Inc., Q4 2014 Earnings Call, Mar 19, 2015

Similar Private Companies By Industry

Company Name Region
Happy Valley Medical, Inc. United States
Giant Funding Corp. United States
Gala Biotech Inc. United States
Prime Synthesis, Inc. United States
Cubist Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zafgen, Inc., please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.